Delaware Chapter of the American College of Cardiology

Join us for the ACC Delaware Chapter Meeting: ACC by the Sea for engaging live education sessions from local, regional, and national experts with Q&A real-time. The educational meeting includes topics of cardio obstetrics, lipids, amyloid, etc., and a chapter update from our Governor Dr. Vinay Hosmane. Participation in this event will earn CME/CNE/and MOC. We look forward to seeing you (IN-PERSON) September 25 - 26, 2026!

For more Information and Register: Delaware ACC By the Sea: 2026 Chapter Meeting

Download the Brochure: Brochure

Delaware Chapter of the American College of Cardiology

Our purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments.

ACC Live Courses

For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

Latest in Cardiology from ACC.org

2027 Hospital OPPS Final Rule: Key Provisions
The Centers for Medicare and Medicaid Services (CMS) has issued the 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System final rule, finalizing a 2.3% increase to OPPS payment rates that reflects a market basket update of 3.2% reduced by a productivity adjustment of 0.9%.
ACCEL Lite: Results of the AFFIRMO Trial
In this episode, Thomas F. Deering MD, FACC and Gregory Y. H. Lip, MD, FACC discuss AFFIRMO: Atrial Fibrillation integrated approach in FraIl, multimoRbid and polyMedicated Older people.
AI in CV Diagnosis: From Smartwatch Screening to Faster Echo Interpretation
Two late-breaking studies presented at AHA 2026 highlight AI's potential to extend cardiovascular screening and improve diagnostic workflow, while underscoring the continued importance of clinician oversight.
ATTAIN-OSA: Orforglipron For Severe OSA in Adults With Obesity or Overweight
Once-daily oral orforglipron improved moderate to severe obstructive sleep apnea (OSA) compared with placebo in adults with obesity or overweight, based on findings from the ATTAIN-OSA trial presented at AHA 2026 and simultaneously published in JAMA.
NCDR Research at AHA 2026: OAC After LAAO; PCI and tMCS in Patients With Ischemic Cardiomyopathy
Explore key findings from two AHA 2026 abstracts using NCDR registry data.